Skip to main content

Advertisement

Table 2 Patient Demographic and Baseline Characteristics (Safety Population)

From: The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis

Patient Demographic and Schizophrenia Characteristics Cariprazine 1.5–3 mg/d n = 170 Cariprazine 4.5–6 mg/d n = 361 Cariprazine 9 mg/d n = 148 Cariprazine Overall N = 679
Age, mean (SD), years 40.2 (10.6) 37.9 (10.8) 38.0 (11.2) 38.5 (10.9)
Male, n (%) 123 (72.4) 249 (69.0) 99 (66.9) 471 (69.4)
Race, n (%)
 White 71 (41.8) 174 (48.2) 57 (38.5) 302 (44.5)
 Black 64 (37.6) 116 (32.1) 60 (40.5) 240 (35.3)
 Asian 17 (10.0) 57 (15.8) 24 (16.2) 98 (14.4)
 Other 8 (4.7) 10 (2.8) 6 (4.1) 24 (3.5)
 Missinga 10 (5.9) 4 (1.1) 1 (0.7) 15 (2.2)
Weight, mean (SD), kg 79.26 (19.15) 77.13 (19.15) 82.69 (22.81) 78.88 (20.09)
Body mass index (BMI), mean (SD), kg/m2 26.96 (5.56) 26.32 (5.43) 27.82 (6.26) 26.81 (5.68)
Duration of schizophrenia, mean (SD), years 12.9 (10.0) 11.4 (9.5) 13.5 (9.9) 12.2 (9.8)
Age at onset, mean (SD), years 27.2 (9.4) 26.4 (9.2) 24.4 (8.6) 26.2 (9.1)
  1. a Race data were not collected in patients from Romania in study RGH-MD-11 per local regulations